Concepts (236)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Early Detection of Cancer | 29 | 2024 | 526 | 4.520 |
Why?
|
| Colorectal Neoplasms | 26 | 2024 | 656 | 4.380 |
Why?
|
| Colonoscopy | 13 | 2024 | 268 | 2.160 |
Why?
|
| Occult Blood | 14 | 2024 | 167 | 1.430 |
Why?
|
| Mass Screening | 13 | 2024 | 690 | 1.060 |
Why?
|
| Patient Compliance | 4 | 2020 | 318 | 0.890 |
Why?
|
| Public Health | 3 | 2020 | 82 | 0.890 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 407 | 0.880 |
Why?
|
| Aged | 39 | 2024 | 6417 | 0.880 |
Why?
|
| Safety-net Providers | 6 | 2020 | 63 | 0.840 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 136 | 0.830 |
Why?
|
| Humans | 56 | 2024 | 18430 | 0.810 |
Why?
|
| Middle Aged | 38 | 2024 | 8284 | 0.800 |
Why?
|
| Electronic Health Records | 9 | 2020 | 747 | 0.750 |
Why?
|
| Female | 41 | 2024 | 13136 | 0.620 |
Why?
|
| Patient Selection | 3 | 2024 | 198 | 0.610 |
Why?
|
| Male | 40 | 2024 | 10440 | 0.610 |
Why?
|
| Postal Service | 8 | 2022 | 83 | 0.600 |
Why?
|
| Community Health Centers | 4 | 2020 | 112 | 0.560 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2016 | 180 | 0.520 |
Why?
|
| Medicaid | 6 | 2024 | 211 | 0.500 |
Why?
|
| Clostridium difficile | 4 | 2016 | 23 | 0.460 |
Why?
|
| Feces | 7 | 2020 | 88 | 0.450 |
Why?
|
| Qualitative Research | 5 | 2024 | 272 | 0.430 |
Why?
|
| Patient Navigation | 2 | 2024 | 17 | 0.410 |
Why?
|
| Colonic Neoplasms | 3 | 2020 | 157 | 0.400 |
Why?
|
| Oregon | 7 | 2023 | 222 | 0.400 |
Why?
|
| Glomerular Filtration Rate | 7 | 2016 | 157 | 0.380 |
Why?
|
| Risk Assessment | 6 | 2019 | 1143 | 0.380 |
Why?
|
| Case Management | 1 | 2010 | 37 | 0.350 |
Why?
|
| Diffusion of Innovation | 1 | 2010 | 44 | 0.350 |
Why?
|
| Evidence-Based Practice | 1 | 2010 | 56 | 0.350 |
Why?
|
| Retrospective Studies | 16 | 2020 | 2550 | 0.350 |
Why?
|
| Kidney Diseases | 4 | 2010 | 55 | 0.340 |
Why?
|
| Northwestern United States | 6 | 2016 | 58 | 0.340 |
Why?
|
| Heart Failure | 2 | 2012 | 398 | 0.320 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2024 | 127 | 0.310 |
Why?
|
| Health Services Accessibility | 3 | 2020 | 320 | 0.310 |
Why?
|
| Medicare | 5 | 2022 | 214 | 0.310 |
Why?
|
| Adult | 16 | 2024 | 7910 | 0.300 |
Why?
|
| Aged, 80 and over | 15 | 2016 | 2003 | 0.300 |
Why?
|
| Attitude of Health Personnel | 3 | 2019 | 226 | 0.300 |
Why?
|
| Ambulatory Care Facilities | 2 | 2020 | 77 | 0.280 |
Why?
|
| United States | 13 | 2024 | 4164 | 0.270 |
Why?
|
| Primary Health Care | 5 | 2024 | 848 | 0.260 |
Why?
|
| Research Design | 3 | 2019 | 402 | 0.260 |
Why?
|
| Kidney Failure, Chronic | 3 | 2012 | 151 | 0.260 |
Why?
|
| Analgesics, Opioid | 3 | 2013 | 241 | 0.260 |
Why?
|
| Hospitalization | 2 | 2010 | 847 | 0.250 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 365 | 0.250 |
Why?
|
| Renal Replacement Therapy | 3 | 2016 | 9 | 0.250 |
Why?
|
| Follow-Up Studies | 9 | 2024 | 1269 | 0.250 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 743 | 0.250 |
Why?
|
| Hispanic Americans | 4 | 2016 | 428 | 0.250 |
Why?
|
| Reminder Systems | 3 | 2023 | 94 | 0.240 |
Why?
|
| Data Accuracy | 1 | 2024 | 27 | 0.240 |
Why?
|
| Information Dissemination | 1 | 2024 | 57 | 0.240 |
Why?
|
| Specimen Handling | 1 | 2024 | 22 | 0.240 |
Why?
|
| Clostridium Infections | 2 | 2016 | 11 | 0.240 |
Why?
|
| Prognosis | 7 | 2020 | 624 | 0.230 |
Why?
|
| Rural Health Services | 1 | 2024 | 14 | 0.230 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2014 | 14 | 0.230 |
Why?
|
| Blood Pressure | 3 | 2016 | 310 | 0.220 |
Why?
|
| Forecasting | 2 | 2020 | 80 | 0.210 |
Why?
|
| Back Pain | 2 | 2013 | 33 | 0.210 |
Why?
|
| Anemia | 2 | 2012 | 32 | 0.190 |
Why?
|
| Precision Medicine | 1 | 2020 | 29 | 0.180 |
Why?
|
| Hemoglobins | 3 | 2016 | 39 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 211 | 0.150 |
Why?
|
| Program Evaluation | 3 | 2020 | 244 | 0.150 |
Why?
|
| Neoplasms | 1 | 2022 | 457 | 0.140 |
Why?
|
| Models, Statistical | 2 | 2016 | 185 | 0.140 |
Why?
|
| Models, Biological | 1 | 2016 | 32 | 0.140 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2017 | 56 | 0.140 |
Why?
|
| Interviews as Topic | 5 | 2017 | 327 | 0.140 |
Why?
|
| Health Maintenance Organizations | 2 | 2010 | 479 | 0.140 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 1360 | 0.140 |
Why?
|
| Risk Management | 1 | 2016 | 5 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 14 | 0.130 |
Why?
|
| Cross Infection | 1 | 2016 | 28 | 0.130 |
Why?
|
| Risk | 2 | 2014 | 552 | 0.130 |
Why?
|
| Cohort Studies | 8 | 2015 | 2672 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2017 | 392 | 0.130 |
Why?
|
| Quality Improvement | 2 | 2020 | 207 | 0.130 |
Why?
|
| Population Surveillance | 2 | 2014 | 271 | 0.120 |
Why?
|
| Public Health Surveillance | 1 | 2014 | 45 | 0.120 |
Why?
|
| Drug Utilization | 2 | 2012 | 134 | 0.120 |
Why?
|
| Individuality | 1 | 2014 | 2 | 0.120 |
Why?
|
| Sodium | 1 | 2014 | 12 | 0.120 |
Why?
|
| Time Factors | 4 | 2019 | 1136 | 0.120 |
Why?
|
| Logistic Models | 3 | 2013 | 962 | 0.120 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 22 | 0.120 |
Why?
|
| Age Factors | 5 | 2016 | 965 | 0.120 |
Why?
|
| Cost Savings | 2 | 2011 | 25 | 0.110 |
Why?
|
| Referral and Consultation | 3 | 2021 | 180 | 0.110 |
Why?
|
| Health Literacy | 1 | 2014 | 40 | 0.110 |
Why?
|
| Perception | 1 | 2013 | 59 | 0.110 |
Why?
|
| Testosterone | 1 | 2013 | 22 | 0.110 |
Why?
|
| Erectile Dysfunction | 1 | 2013 | 25 | 0.110 |
Why?
|
| Incidence | 5 | 2020 | 1314 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2014 | 112 | 0.110 |
Why?
|
| Research Report | 1 | 2012 | 22 | 0.110 |
Why?
|
| Aging | 1 | 2014 | 165 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2014 | 266 | 0.100 |
Why?
|
| Benchmarking | 1 | 2012 | 45 | 0.100 |
Why?
|
| Low Back Pain | 1 | 2012 | 55 | 0.100 |
Why?
|
| Proteinuria | 1 | 2012 | 26 | 0.100 |
Why?
|
| Preventive Health Services | 1 | 2014 | 166 | 0.100 |
Why?
|
| Physicians, Primary Care | 1 | 2012 | 74 | 0.100 |
Why?
|
| Health Expenditures | 1 | 2012 | 82 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2022 | 1296 | 0.100 |
Why?
|
| Laboratories | 1 | 2011 | 23 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2011 | 41 | 0.090 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 17 | 0.090 |
Why?
|
| Systole | 3 | 2016 | 22 | 0.090 |
Why?
|
| Telephone | 2 | 2023 | 179 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2012 | 251 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 197 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 3 | 2019 | 270 | 0.090 |
Why?
|
| Lisinopril | 1 | 2010 | 5 | 0.090 |
Why?
|
| Washington | 3 | 2019 | 388 | 0.090 |
Why?
|
| Hyperkalemia | 1 | 2010 | 17 | 0.090 |
Why?
|
| Young Adult | 5 | 2016 | 2518 | 0.090 |
Why?
|
| Phosphorus | 1 | 2009 | 6 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 90 | 0.080 |
Why?
|
| Health Services Research | 1 | 2010 | 264 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2011 | 350 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 342 | 0.080 |
Why?
|
| Colorado | 3 | 2014 | 211 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 476 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2010 | 256 | 0.080 |
Why?
|
| Comorbidity | 3 | 2014 | 619 | 0.070 |
Why?
|
| Efficiency, Organizational | 1 | 2007 | 36 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2007 | 55 | 0.070 |
Why?
|
| Osteoporosis | 1 | 2007 | 76 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2007 | 91 | 0.070 |
Why?
|
| Chronic Disease | 4 | 2010 | 468 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 133 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2019 | 237 | 0.070 |
Why?
|
| Communication | 2 | 2019 | 202 | 0.060 |
Why?
|
| Internet | 1 | 2007 | 243 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 131 | 0.060 |
Why?
|
| Rural Population | 1 | 2024 | 52 | 0.060 |
Why?
|
| Community-Institutional Relations | 1 | 2024 | 47 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 630 | 0.050 |
Why?
|
| Sex Factors | 2 | 2016 | 661 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 2 | 2012 | 17 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2012 | 253 | 0.050 |
Why?
|
| Drug Prescriptions | 2 | 2013 | 157 | 0.050 |
Why?
|
| Health Services | 2 | 2012 | 117 | 0.050 |
Why?
|
| California | 2 | 2019 | 2365 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 673 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 105 | 0.050 |
Why?
|
| Morbidity | 1 | 2021 | 62 | 0.050 |
Why?
|
| Health Behavior | 2 | 2014 | 374 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2012 | 701 | 0.050 |
Why?
|
| Biomarkers | 2 | 2012 | 308 | 0.040 |
Why?
|
| Immunochemistry | 1 | 2020 | 19 | 0.040 |
Why?
|
| Risk Factors | 3 | 2014 | 3449 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 81 | 0.040 |
Why?
|
| Adolescent | 2 | 2022 | 3798 | 0.040 |
Why?
|
| Mental Disorders | 2 | 2012 | 295 | 0.040 |
Why?
|
| Text Messaging | 1 | 2019 | 31 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 529 | 0.040 |
Why?
|
| Prevalence | 2 | 2013 | 911 | 0.040 |
Why?
|
| Patient Participation | 1 | 2019 | 144 | 0.040 |
Why?
|
| Organizational Culture | 1 | 2017 | 18 | 0.040 |
Why?
|
| Awareness | 1 | 2017 | 18 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2017 | 12 | 0.040 |
Why?
|
| Leadership | 1 | 2017 | 45 | 0.040 |
Why?
|
| Albuminuria | 1 | 2016 | 41 | 0.040 |
Why?
|
| Health Promotion | 1 | 2019 | 294 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1173 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2020 | 1314 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2016 | 119 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 15 | 0.030 |
Why?
|
| British Columbia | 1 | 2015 | 4 | 0.030 |
Why?
|
| Patient Admission | 1 | 2016 | 76 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 172 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 185 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 47 | 0.030 |
Why?
|
| Comprehension | 1 | 2014 | 16 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 93 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 1389 | 0.030 |
Why?
|
| Creatinine | 1 | 2014 | 65 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 46 | 0.030 |
Why?
|
| Financing, Government | 1 | 2014 | 32 | 0.030 |
Why?
|
| Language | 1 | 2014 | 52 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 399 | 0.030 |
Why?
|
| Vardenafil Dihydrochloride | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tadalafil | 1 | 2013 | 2 | 0.030 |
Why?
|
| Carbolines | 1 | 2013 | 2 | 0.030 |
Why?
|
| Sulfones | 1 | 2013 | 2 | 0.030 |
Why?
|
| Triazines | 1 | 2013 | 2 | 0.030 |
Why?
|
| Urological Agents | 1 | 2013 | 2 | 0.030 |
Why?
|
| Purines | 1 | 2013 | 3 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 4 | 0.030 |
Why?
|
| Sildenafil Citrate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Piperazines | 1 | 2013 | 9 | 0.030 |
Why?
|
| Androgens | 1 | 2013 | 13 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 28 | 0.030 |
Why?
|
| Vancomycin | 1 | 2012 | 3 | 0.030 |
Why?
|
| Metronidazole | 1 | 2012 | 4 | 0.030 |
Why?
|
| Demography | 1 | 2012 | 108 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2012 | 34 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2012 | 100 | 0.030 |
Why?
|
| ROC Curve | 1 | 2012 | 83 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2014 | 346 | 0.030 |
Why?
|
| Health Records, Personal | 1 | 2011 | 13 | 0.020 |
Why?
|
| Outpatients | 1 | 2012 | 111 | 0.020 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 110 | 0.020 |
Why?
|
| Drug Overdose | 1 | 2012 | 57 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 47 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 724 | 0.020 |
Why?
|
| Patient Safety | 1 | 2011 | 41 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2013 | 217 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 321 | 0.020 |
Why?
|
| Decision Making | 1 | 2012 | 204 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2012 | 254 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 271 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 142 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2011 | 147 | 0.020 |
Why?
|
| Smoking | 1 | 2013 | 494 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 269 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 333 | 0.020 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2009 | 2 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2011 | 347 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 342 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 226 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 1245 | 0.020 |
Why?
|
| Depression | 1 | 2013 | 518 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 1478 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 52 | 0.020 |
Why?
|
| Organizations, Nonprofit | 1 | 2007 | 11 | 0.020 |
Why?
|
| Bone Density | 1 | 2007 | 96 | 0.020 |
Why?
|
| Child | 1 | 2012 | 2571 | 0.020 |
Why?
|
Concepts
(236)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(12)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->